The role of the microbiome and notch signaling in esophageal adenocarcinoma

Active Project Grant Awarded Last action

Award ID
R01CA255298
Recipient
Awarding agency
Obligated
$13,948,122

Award facts

Assistance listing
93.396 Cancer Biology Research
Completion date 97% complete
Originally
Funding
  • $13,198,951.00 Federal
  • $749,171.00 Non-federal
Place of performance
New York, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
The incidence of esophageal adenocarcinoma (EAC) has risen 10-fold over the past half century and continues to have a dismal prognosis. Known modifiable risk factors for EAC do not adequately explain these incidence trends; the rise in EAC cases began a decade before increases in the prevalence of both gastro- esophageal reflux disease and obesity. Helicobacter pylori infection rates have plummeted since the mid-20TH century, and absence of h. Pylori is associated with a ~2-fold increased risk of barrett's esophagus (be), the EAC precursor lesion, and of EAC itself. Loss of h. Pylori is associated with profound shifts to gastric microbiome composition. Thus, dramatic changes in the upper GI microbiome in western populations likely occurred at the same time that be and subsequently EAC began to rise in incidence. While prior work has shown correlations between the microbiome, be, and EAC, there is a critical knowledge GAP on mechanisms by which bacteria interact with the epithelium and potentially promote cancer. The mucus layer that overlies the GUT epithelium is critical to maintaining host-bacteria homeostasis. We hypothesize that increased levels of the bile acid deoxycholic acid in gastro-esophageal refluxate results in increased notch activity, which in turn inhibits goblet cell differentiation and decreases mucus production. This may lead to mucus layer thinning, facilitating the development of biofilms and leading to increased bacterial-epithelial interaction and chronic inflammation, which promotes the development of esophageal adenocarcinoma (EAC). In aim 1, we will carry out a case-control study of patients with and without be, dysplasia, or EAC. We will focus on deoxycholic acid in gastro-esophageal refluxate and its association with notch signaling and bacterial composition. In aim 2, we focus on the relationship between notch signaling and enterobacteriaceae, which is increased in patients with high grade dysplasia and early EAC. Finally, in aim 3, we will perform a series of organoid-based experiments to test the inter-relatedness between notch, deoxycholic acid, and bacteria in be. The microbiome represents a novel and potentially modifiable risk factor for the development of be and EAC. Elucidation of microbiome features and mechanisms that promote neoplasia is a critical step that will lead to subsequent trials of antibiotics, probiotics, and other interventions targeted to altering the microbiome, with the goal of lowering the risk of this highly lethal malignancy.

Transactions

Action Obligated Date
Amendment $0
Amendment $46,616
Amendment $46,616
Amendment $0
Amendment $0
Amendment $0
Amendment $419,550
Amendment $419,550
Amendment $419,550
Amendment $419,550
Amendment $99,686
Amendment $99,686
Amendment -$99,686
Amendment -$99,686
Amendment -$99,686
Amendment -$94,441
Amendment $99,686
Amendment $99,686
Amendment -$94,441
Amendment -$94,441
Amendment $99,686
Amendment $24,652
Amendment $24,652
Amendment $24,652
Amendment $24,652
Amendment $24,652
Amendment $24,652
Amendment $24,652
Amendment $94,441
Amendment $94,441
Amendment $94,441
Amendment $94,441
Amendment $94,441
Amendment $94,441
Amendment $94,441
Amendment $94,441
Amendment $443,752
Amendment $443,752
Amendment $443,752
Amendment $443,752
Amendment $443,752
Amendment $443,752
Amendment $443,752
Amendment $443,752
Amendment $70,807
Amendment $70,807
Amendment $70,807
Amendment $70,807
Amendment $70,807
Amendment $523,932
Show 40 more

Latest 50 listed here. See the rest on GovTribe.

Subawards

Subrecipient Amount Awarded
Universitatsklinikum Freiburg Aim 3 will be carried out largely in the lab of Dr. Michael Quante at Frieburg Medical University. In this aim, we propose to perform a series of organoid-based… $44,673
Universitatsklinikum Freiburg $49,637
The Trustees Of The University Of Pennsylvania SCOPE OF WORK Principal Investigator: Julian Abrams, MD, MS (Columbia University) Co-Investigator :Felice Schnoll-Sussman, MD (Weill Cornell Medical Center)… $48,287

Quick answers

Who received award R01CA255298?

R01CA255298 was awarded to The Trustees Of Columbia University In The City Of New York by National Cancer Institute (National Institutes of Health) on January 1, 2021.

How much is award R01CA255298 worth?

$13,948,122 has been obligated on R01CA255298: $13,198,951 in federal funding and $749,171 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login